The much hyped Supreme Court ruling in June 2013, which declared that isolated human genes are not patentable, has significantly challenged Myriad Genetics' (NASDAQ:MYGN) patent landscape. The stock has seen ~50% correction following the incident. However, I believe that the company's recent move to market Sividon Diagnostics' breast cancer test EndoPredict in Europe is a positive development. This, coupled with the company's plans to transform the entire hereditary cancer market towards myRisk platform through fiscal 2015, is expected to drive the stock higher again over the medium-term.
MYGN data by YCharts
What Went Wrong?
MYGN offers the following molecular diagnostic tests:
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|